VTRS vs MRK vs PFE vs ABBV

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate Merck & Co. , Inc. (MRK) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, Viatris Inc. is actually cheaper at 7. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus VTRS's -51. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Viatris Inc. 's 0. 99β — meaning VTRS is approximately 194% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Merck & Co. , Inc. grew EPS 8. 0% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, MRK leads at 3. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Viatris Inc.

(VTRS) trades at 7. 1x forward P/E versus 21. 9x for Merck & Co. , Inc. — 14. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 26. 6% to $256. 64.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 2. 8% for Viatris Inc. (VTRS).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, VTRS: -51. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTRS is a mid-cap quality compounder stock; MRK is a large-cap deep-value stock; PFE is a mid-cap income-oriented stock; ABBV is a large-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.